GLP-1 receptor agonist drugs like Ozempic, Wegovy and Mounjaro have helped millions of Americans lose weight and better manage their type 2 diabetes. And as of December 20, Eli Lilly’s weight ...

Starting July 1, CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor Novo Nordisk, will still be covered under plans managed ...

Eli Lilly (NYSE: LLY) has been growing its sales at a good clip over the past year. This is partly thanks to Zepbound, a weight loss medicine that's already generating more than $1 billion in ...

Eli Lilly's blockbuster diabetes treatment Mounjaro topped expectations for the first quarter, raking in $3.84 billion in revenue. That's up a whopping 113% from the same period a year ago.

Eli, who was not elected to the Hall of Fame in his first try, claimed he was ready to go. Peyton Manning’s kick hits the right upright during FanDuel’s Kick of Destiny on Feb. 9, 2025.

ZIM Integrated (ZIM) surged 6.8% amid takeover speculation by CEO Eli Glickman. Stay updated as Q4 results are set to release this Wednesday.

Eli Lilly has unveiled plans to invest $27 billion in the construction of four new manufacturing plants in the United States. Getty Images The new sites will be announced later this year and are ...

Eli Lilly is doubling its U.S. manufacturing investment since 2020 as it seeks to produce more drugs domestically. Its latest investment is to the tune of $27 billion.